Nasser H. Hanna - Concepedia

Author

Nasser H. Hanna

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Birdas, Thomas J., Fakiris, Achilles J., Mosher, Catherine E., N HANNA, N Hanna, N. H. Hanna, N. HANNA, N. Hanna, N.H. Hanna, NASSER H. HANNA

469

Publications

16.3K

Citations

H-Index

124

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Indiana University Health Hoosier Cancer Research Network (United States)Northern Indiana Cancer Research Consortium

About

Nasser H. Hanna is an author at Indiana University – Purdue University Indianapolis specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	97	6.2K
2	Health Sciences	21	32	2K
3	Nursing	6	6	403
4	Public Health	6	6	495
5	Arts	1	1	36

Nasser H. Hanna

139

Publications

13.8K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Journal of Clinical Oncology	2004	2.4K
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer Nasser H. Hanna, Paul A. Bunn, Corey J. Langer, Journal of Clinical Oncology	2006	673
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Nasser H. Hanna, David H. Johnson, Sarah Temin, Journal of Clinical Oncology	2017	643
Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology Nasser H. Hanna, Marcus A. Neubauer, Constantin T. Yiannoutsos, Journal of Clinical Oncology	2008	492
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, Journal of Clinical Oncology Cp ChemotherapyMedicinePhase IiiPharmacologyClinical Trials	2010	453
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna, Bryan J. Schneider, Sarah Temin, Journal of Clinical Oncology	2020	444
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Nasser H. Hanna Yearbook of Oncology Radiation OncologyMedicineCancer GrowthCancer BiologyGefitinib Resistance	2008	383
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) George R. Blumenschein, Egbert F. Smit, David Planchard, Annals of Oncology Non-small-cell Lung CancerMedicinePharmacologyPathologyCancer Cell Biology	2015	355
EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib Nasser H. Hanna Yearbook of Oncology OncologyMedicinePathologyCancer GenomicsCancer Genetics	2006	340
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations Toru Mukohara, Jeffrey A. Engelman, Nasser H. Hanna, JNCI Journal of the National Cancer Institute	2005	317

Page 1